Author:
Chihana Rachel,Jin Kee Jia,Moodie Zoe,Huang Yunda,Janes Holly,Dadabhai Sufia,Roxby Alison C.,Allen Mary,Kassim Sheetal,Naicker Vimla,Innes Craig,Naicker Nivashnee,Dubula Thozama,Grunenberg Nicole,Malahleha Mookho,Kublin James G.,Bekker Linda-Gail,Gray Glenda,Kumwenda Johnstone,Laher Fatima
Funder
National Institute of Allergy and Infectious Diseases
Bill & Melinda Gates Foundation
Novartis Vaccines and Diagnostics Inc
Reference17 articles.
1. Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Da Silva FT. The how’s and what’s of vaccine reactogenicity. Vol. 4, npj Vaccines. 2019.
2. Laher F, Bekker LG, Garrett N, Lazarus EM, Gray GE. Review of preventative HIV vaccine clinical trials in South Africa. Vol. 165, Archives of Virology. 2020. p. 2439–52.
3. Potential factors influencing COVID-19 vaccine acceptance and hesitancy: A systematic review;Roy;PLoS One,2022
4. Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines–Early experience with vaccine rollout in a multi-site healthcare system;Al-Obaydi;PLoS One,2022
5. Analysis of the HIV vaccine trials network 702 phase 2b–3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk;Moodie;J Infect Dis,2022